| Followers | 258 |
| Posts | 19732 |
| Boards Moderated | 0 |
| Alias Born | 10/03/2004 |
Wednesday, December 09, 2009 12:25:37 PM
>>"And the fact that the treatment can be considered only a temporary cure, because after treatment, it is possible to be re-infected with the virus,"
In nearly all viral infections, the virus compromises the immune system in some way, whether it is by overwhelming the system with viral matter (Ebola) or hijacking key elements for its own use (HIV). Seymour has already talked about how following infection and nanoviricide treatment, it appears that immune systems are educated against the virus and can more rapidly respond to new infections or reinfections.
Second, there are no approved treatments for viral infections, other than neuraminidase inhibitors, which also does not include the immune system; those instead inhibit either entry or exit of viral matter infecting host cells. The only things are vaccines, which actions are prophylactic and have no effect after infection. Vaccines are not treatments.
In nearly all viral infections, the virus compromises the immune system in some way, whether it is by overwhelming the system with viral matter (Ebola) or hijacking key elements for its own use (HIV). Seymour has already talked about how following infection and nanoviricide treatment, it appears that immune systems are educated against the virus and can more rapidly respond to new infections or reinfections.
Second, there are no approved treatments for viral infections, other than neuraminidase inhibitors, which also does not include the immune system; those instead inhibit either entry or exit of viral matter infecting host cells. The only things are vaccines, which actions are prophylactic and have no effect after infection. Vaccines are not treatments.
Recent NNVC News
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2025 09:07:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/29/2025 08:33:17 PM

